Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Income from Continuing Operations (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Income from Continuing Operations data on record, last reported at 16941000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations changed 0.36% year-over-year to 16941000.0; the TTM value through Sep 2025 reached 73446000.0, down 5.42%, while the annual FY2024 figure was 74275000.0, 22.27% down from the prior year.
  • Income from Continuing Operations reached 16941000.0 in Q3 2025 per NWBO's latest filing, down from 16605000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 13214000.0 in Q2 2021 and bottomed at 22531000.0 in Q2 2022.
  • Average Income from Continuing Operations over 5 years is 17350764.71, with a median of 16941000.0 recorded in 2025.
  • Peak YoY movement for Income from Continuing Operations: crashed 148.49% in 2021, then surged 33.96% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 13214000.0 in 2021, then plummeted by 46.81% to 19399000.0 in 2022, then grew by 15.54% to 16384000.0 in 2023, then dropped by 28.09% to 20987000.0 in 2024, then increased by 19.28% to 16941000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 16941000.0 in Q3 2025, 16605000.0 in Q2 2025, and 18913000.0 in Q1 2025.